## Meet Mold By Kheiron Medical

### Giving every woman, everywhere a better fighting chance against breast cancer

Mia<sup>®</sup> is our breakthrough AI platform for breast screening. A suite of solutions, Mia is designed to empower radiologists and screening services to deliver confident, accurate and timely results to every woman, everywhere.

## Mia delivers **gold standard** double-reading quality with a single human reader

# Mia<sup>®</sup>

Available to use in various configurations such as an independent second reader, a concurrent reader or in double reader triage. Mia supports radiologists in making the most important breast screening decision — should a woman be called back for further testing or not?

Mia addresses the key problems facing breast screening services including:

- variable performance
- missed cancers
- high recall rates
- growing shortage of radiologists

Making this critical 'call-back' decision is the most useful way to support radiologists, reducing their workload, increasing screening efficiency and dramatically improving the patient experience. It also delivers quality improvements for providers and ensures the sustainability of breast screening services. Mia's ground-breaking performance in our first clinical study showed that Mia operates at 90% sensitivity and 89% specificity on a representative screening population. These state-of-the-art results led to Mia being one of the first Al radiology products in the UK to receive a CE Mark (EU regulatory clearance). As far as we know, Mia was also the first Al breast screening solution to be regulatory cleared as an independent reader.

With patient safety and clinical rigor at the heart of our mission, we are going beyond what current regulations require to ensure and prove that Mia is the best-performing Al software for breast cancer screening and that it is safe for all women. Our second clinical study - a multi-site, multi-hardware and multi-country study, with more than 250,000 cases from real world screening populations - is one of the most ambitious clinical studies in radiology Al to date. The study demonstrates that Mia is a clinically safe and cost-effective option for providing gold standard double-reading quality with a single human reader.



### Radiologists

Reduce missed cancers

Lower false positives
Increase productivity



### Providers

>Immediate cost savings


- $\rightarrow$  Increase standardization  $\rightarrow$  Mitigate radiologist
  - shortages



#### Women

 $\rightarrow$  Reliable cancer detection

- $\rightarrow$  Reduce recalls & anxiety
- Avoid unnecessary biopsies



Variable Mia configurations are available for double reader and single reader workflows



Learn more about how Kheiron is developing AI to transform breast cancer screening. Visit <u>www.kheironmed.com</u> or email <u>info@kheironmed.com</u>